AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and Chief Executive Officer, will present an overview of the Company at two upcoming investor conferences. Dr. Pereira will present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008 at 8:35 a.m. ET and at the Baird 2008 Small Cap Healthcare Conference on September 10, 2008 at 9:30 a.m. ET. Both conferences will take place in New York City.
A live audio webcast of both presentations will be accessible through the Investors section of the Company’s website at www.amagpharma.com. Following the conferences, the webcasts will be archived on the AMAG Pharmaceuticals, Inc. website until October 1, 2008.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.
Ferumoxytol, the Company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia and as a diagnostic agent for vascular-enhanced magnetic resonance imaging to assess peripheral arterial disease. The Company submitted a New Drug Application (NDA) for marketing approval of ferumoxytol as an intravenous iron replacement therapy in chronic kidney disease patients with the U.S. Food and Drug Administration (FDA) in December 2007. The Company expects FDA action on its NDA in the second half of October 2008.
Forward-Looking Statement
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to, statements regarding our expectation of FDA action on our ferumoxytol NDA in the second half of October 2008 are forward looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward looking statements. Such risks and uncertainties include:
(1) The possibility that we may not be able to obtain the necessary regulatory approvals in order to market and sell ferumoxytol, or we may not obtain such approvals in a timely manner due to deficiencies in the design or oversight by us of our clinical trials, the failure of our trials to demonstrate that ferumoxytol is safe and effective, or any other factor causing an increase in expenses, a delay and/or a negative effect on the results of our clinical studies or the prospects for regulatory approval of ferumoxytol, (2) the fact that we have limited sales and marketing expertise, (3) uncertainties regarding our ability to successfully compete in the intravenous iron replacement and imaging markets, (4) uncertainties regarding our ability to obtain favorable coverage, pricing and reimbursement for ferumoxytol, if approved, (5) uncertainties regarding our ability to manufacture sufficient quantities of ferumoxytol to meet demand, if approved, (6) uncertainties relating to our patents and proprietary rights, and (7) other risks identified in our Securities and Exchange Commission filings, including our most recent Annual Report on Form 10-K.
We caution readers not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Contacts:
Carol Miceli, 617-498-3361
cmiceli@amagpharma.com
